Wolverine Legal Status, FDA 503A Category, and Compounding Access

Access is restricted today — and under active FDA review

Wolverine legal status starts with one present-tense fact and one piece of forward momentum. The fact: both constituents of the BPC-157 TB-500 blend are bulk drug substances that the FDA placed in 503A "Category 2" — substances FDA identified as raising significant safety risks — effective with the September 29, 2023 update to the list of substances nominated for use under section 503A ^[13]. The momentum: that classification is not the end of the story. Access is under active FDA review and may expand, anchored on a scheduled advisory-committee meeting in 2026.

Category 2 has a specific consequence. FDA's interim policy does not extend its enforcement-discretion to Category 2 substances; FDA stated it would consider taking action against a compounder for compounding with one ^[14]. In plain terms, compounding-pharmacy access to these peptides is currently restricted while that status stands. Neither BPC-157 nor TB-500 is an FDA-approved drug, and the Wolverine blend has no approved indication ^[13].

That is where the present tense ends. What comes next is a scheduled review, not a settled outcome — and the distinction matters, because it is the entire reason the picture is described here as restricted-but-moving rather than simply closed.

The scheduled July 2026 FDA advisory-committee review

The forward-leaning part of this page rests on a single dated, FDA-citable fact: a meeting of the FDA Pharmacy Compounding Advisory Committee (PCAC) is scheduled for July 23-24, 2026, to discuss bulk drug substances being considered for inclusion on the 503A bulks list ^[15]. Both of the Wolverine blend's constituents are on that agenda.

BPC-157 (listed as "BPC-157 (free base)" / "BPC-157 acetate") appears on the published agenda as a substance being considered for inclusion on the 503A bulks list ^[13][15]. TB-500 (listed as "TB-500 (free base)" / "TB-500 acetate," the LKKTETQ fragment FDA associates with thymosin beta-4) appears on the same agenda, in the same capacity ^[13][15]. There is no component carve-out: both peptides are currently Category 2, and both are under this one scheduled review.

What this meeting is, and is not, has to be stated carefully. Inclusion on a final 503A bulks list is decided by FDA rulemaking informed by the committee; being discussed by the committee is a step in evaluation, not a final listing decision ^[14]. The meeting may expand access — that is its momentum — but no reclassification has occurred, none is dated, and none is certain. Anyone reading a vendor claim that these peptides were "moved back" or "removed" on a specific 2026 date should treat it as unconfirmed: the fact that both remain on the July 2026 agenda as candidates is consistent with their evaluation being ongoing rather than resolved ^[15].

How legally compounded peptide access works

U.S. drug compounding runs through two sections of the Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies, federal facilities, and licensed physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that compound larger batches under cGMP-style oversight ^[14].

In general terms, a legally compounding pharmacy access pathway looks like this ^[16]:

1. A patient is evaluated by an appropriately licensed prescriber — in person or via a compliant telehealth encounter — who determines whether a compounded preparation is clinically appropriate.
2. If appropriate and lawful, the prescriber issues a valid, patient-specific prescription.
3. The prescription is dispensed by a state-licensed 503A compounding pharmacy, or, for office or batch use, sourced from an FDA-registered 503B outsourcing facility.

Telehealth is one channel for the prescriber-evaluation step that begins this pathway — a route to a licensed-prescriber consultation and prescription, not a separate legal status. It does not expand which substances may be compounded and does not remove the need for a legitimate clinical evaluation and a valid prescription ^[16].

The ingredient-eligibility caveat is the part that bears on these peptides directly. A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list ^[14]. Substances FDA has flagged for significant safety risks — which is where BPC-157 and TB-500 sit today — are not eligible for routine 503A compounding while that status stands ^[13][16]. This is general information about the regulatory landscape, not medical or legal advice, and not an offer to supply any substance.

Is the Wolverine Blend Legal?

Neither constituent is an FDA-approved drug, and the blend has no approved indication. Both BPC-157 and TB-500 are 503A Category 2 bulk substances FDA identified as raising significant safety risks, effective the September 29, 2023 list update, so compounding-pharmacy access is currently restricted ^[13]. Both are on the scheduled July 23-24, 2026 FDA advisory-committee agenda as candidates for the 503A bulks list — a scheduled discussion, not a decision ^[15].

BPC-157 and Compounding Pharmacy Access

BPC-157 is in 503A Category 2, which is outside FDA's enforcement-discretion policy, so routine compounding-pharmacy access is restricted while that status stands ^[13][14]. A lawful compounded preparation requires a licensed-prescriber evaluation, a valid patient-specific prescription, and an eligible ingredient; BPC-157's Category 2 status is the reason the ingredient-eligibility step is currently the binding constraint ^[16].

FDA 503A Status of the Blend

Both constituents are 503A Category 2 bulk drug substances, effective the September 29, 2023 update to FDA's nominated-substances list ^[13]. Category 2 means FDA identified significant safety risks and does not extend enforcement-discretion to the substance ^[14]. Both BPC-157 and TB-500 are on the scheduled July 23-24, 2026 PCAC agenda as candidates for the 503A bulks list — a scheduled evaluation, not a change in current status ^[15].